A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon) on Glucose Control in Patients With Type I Diabetes
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Exenatide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 05 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018.
- 05 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated